In designing the operation, it had always intended on expanding there, adding one of the biologic products that are becoming more important to its future.
Bristol-Myers Squibb has inked a preferred provider deal with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments.
Bristol-Myers Squibb--which startled the industry earlier this week with its plans to transition in a new R&D chief--has blueprinted a $250 million expansion of its biologics manufacturing facility in Devens, near I-495.
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
In a Monday scramble aimed at convincing the Street that the company is pursuing the same largely successful course mapped out by Sigal and his team, a group of top executives including the newly appointed research chief vowed to keep a strong grasp on its widely lauded "string of pearls" approach to R&D--particularly when it comes to new cancer drugs that spur the immune system.
Bristol-Myers Squibb has reached into its R&D organization to find a replacement for R&D chief Elliott Sigal, the latest in a string of biopharma research chiefs to find himself facing an early retirement.
CROs competing for big-name deals may face a more crowded market now that on-the-ropes diagnostics companies are getting into the clinical research game, something LabCorp demonstrated this week as it inked a preferred-provider contract with Bristol-Myers Squibb.
Vertex Pharmaceuticals has found another ally as the company plays catch up in the race to advance all-oral therapies against hepatitis C. Vertex and Bristol-Myers Squibb have agreed to combine experimental compounds to test in Phase II trials, the first of which will kick off during the current fiscal quarter.
Bristol-Myers Squibb is rolling up the Amylin tent in San Diego. After buying the smaller drugmaker last year, Bristol-Myers plans to shut down its former headquarters and lay off at least 400 workers.
Now that Bristol-Myers Squibb has taken full control of Amylin's diabetes drugs, it's time to sweep up after the merger party. BMS says it is closing down the storied, 266,000-square-foot headquarters facility in La Jolla at the end of next year, with plans to lay off all among the 420 remaining staffers who don't make a transfer.